Minimizing Toxicity and Boosting Immunity with Targeted Cancer Treatment
According to the National Cancer Institute, more than 1.7 million people are diagnosed with cancer every year in the United States, and approximately 38% of people will be diagnosed with cancer during their lifetimes. While there are many options for cancer treatment already on the market, these one-size-fits-all approaches often come with widespread side effects and, for some patients, those treatments simply aren’t effective. Our CEO success spotlight features Jennifer MacDiarmid, CEO of EnGeneIC, to discuss how her company’s targeted cyto-immunotherapeutic nanocell is offering hope to those with drug-resistant cancers.
For more information on EnGeneIC, visit www.engeneic.com.